USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DESIGNMEDIX, INC.
Address:
2828 Corbett Ave Suite 140A
PORTLAND, OR 97201-4830
Phone:
N/A
URL:
N/A
EIN:
262779288
DUNS:
623389009
Number of Employees:
4
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $102,614.00 1
STTR Phase I $703,876.00 2
STTR Phase II $1,327,608.00 1

Award List:

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$103,876.00
Agency:
HHS
Principal Investigator:
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replace ment drug, we have developed a novel class… More

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$1,327,608.00
Agency:
HHS
Principal Investigator:
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-resistant malaria. Preliminary data showed that this novel class of molecules, called reversed… More

Preclinical development of novel small molecule malaria drugs that overcome drug

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
David H. Peyton – 503-725-3875
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to… More

Optimization of a novel antimalarial drug candidate for plant-scale synthesis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$102,614.00
Agency:
HHS
Principal Investigator:
Steven Burgess – 503-484-7026
Abstract:
DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths… More